Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Viral Hepatitis

• Publication date

  2012-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2893.2011.01446.xPMID 22239500
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long‐term effectiveness and cost‐effectiveness of antiviral treatment in hepatitis C

  2010cited by this paper
• The impact of a managed care network on attendance, follow‐up and treatment at a hepatitis C specialist centre

  2010cited by this paper
• Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden

  2006cited by this paper
• Variation in Hepatitis C services may lead to inequity of heath-care provision: a survey of the organisation and delivery of services in the United Kingdom

  2006cited by this paper
• Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries.

  2005cited by this paper
• Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: A systematic review and economic evaluation

  2005cited by this paper
• Barriers to the treatment of hepatitis C. Patient, provider, and system factors.

  2005cited by this paper
• Global epidemiology of hepatitis C virus infection.

  2005cited by this paper
• Peginterferon-2a and Ribavirin Combination Therapy in Chronic Hepatitis C

  2004cited by this paper
• Global Burden of Disease (GBD) for Hepatitis C

  2004cited by this paper
• Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

  2004cited by this paper
• Global Epidemiology of Hepatitis B Virus

  2004cited by this paper
• A cost‐effectiveness analysis of peginterferon alfa‐2b plus ribavirin for the treatment of naive patients with chronic hepatitis C

  2003cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Hepatitis C virus seroconversion among young injection drug users: relationships and risks.

  2002cited by this paper
• Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

  2001cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Improving ascertainment and treatment rates of chronic viral hepatitis

  2017cites this paper
• Multidisciplinary managed care networks—Life‐saving interventions for hepatitis C patients

  2017cites this paper
• Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version, April 2016.

  2016cites this paper
• Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection.

  2015cites this paper
• Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral

  2015cites this paper
• Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden

  2015cites this paper
• Recommendations for the management of hepatitis C virus infection among people who inject drugs.

  2015cites this paper
• HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact

  2014cites this paper
• Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

  2014cites this paper
• Setting Standards in a Journey towards the Eradication of Infection and Disease as a Serious Health Issue in the EU

  2014cites this paper
• Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis.

  2013influential citation
• Recommendations for the management of hepatitis C virus infection among people who inject drugs.

  2013cites this paper
• Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy.

  2013cites this paper
• Treatment decisions and contemporary versus pending treatments for hepatitis C

  2013cites this paper
• The comparison of chronic hepatitis C treatment outcome between intravenous drug users and non-intravenous drug users.

  2013cites this paper
• Telaprevir: Clinical Pharmacokinetics, Pharmacodynamics, and Drug–Drug Interactions

  2013cites this paper
• Dry blood spot testing for hepatitis C in people who injected drugs: reaching the populations other tests cannot reach

  2013cites this paper
• Chronic Hepatitis C Infection: Clinical and Societal Evaluations

  2013influential citation
• Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: early effects of active substance use.

  2013cites this paper
• Influence of Healthcare-Associated Factors on the Efficacy of Hepatitis C Therapy

  2012cites this paper
• <scp>HCV</scp> treatment rates and sustained viral response among people who inject drugs in seven <scp>UK</scp> sites: real world results and modelling of treatment impact

  year unknowncites this paper